These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 22224940)

  • 1. Prospects for primary stroke prevention in children with sickle cell anaemia.
    Jordan LC; Casella JF; DeBaun MR
    Br J Haematol; 2012 Apr; 157(1):14-25. PubMed ID: 22224940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.
    Ware RE; Davis BR; Schultz WH; Brown RC; Aygun B; Sarnaik S; Odame I; Fuh B; George A; Owen W; Luchtman-Jones L; Rogers ZR; Hilliard L; Gauger C; Piccone C; Lee MT; Kwiatkowski JL; Jackson S; Miller ST; Roberts C; Heeney MM; Kalfa TA; Nelson S; Imran H; Nottage K; Alvarez O; Rhodes M; Thompson AA; Rothman JA; Helton KJ; Roberts D; Coleman J; Bonner MJ; Kutlar A; Patel N; Wood J; Piller L; Wei P; Luden J; Mortier NA; Stuber SE; Luban NLC; Cohen AR; Pressel S; Adams RJ
    Lancet; 2016 Feb; 387(10019):661-670. PubMed ID: 26670617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.
    Cherry MG; Greenhalgh J; Osipenko L; Venkatachalam M; Boland A; Dundar Y; Marsh K; Dickson R; Rees DC
    Health Technol Assess; 2012; 16(43):1-129. PubMed ID: 23140544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.
    Fortin PM; Hopewell S; Estcourt LJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012082. PubMed ID: 30067867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial.
    Abdullahi SU; Jibir BW; Bello-Manga H; Gambo S; Inuwa H; Tijjani AG; Idris N; Galadanci A; Hikima MS; Galadanci N; Borodo A; Tabari AM; Haliru L; Suleiman A; Ibrahim J; Greene BC; Ghafuri DL; Rodeghier M; Slaughter JC; Kirkham FJ; Neville K; Kassim A; Trevathan E; Jordan LC; Aliyu MH; DeBaun MR
    Lancet Haematol; 2022 Jan; 9(1):e26-e37. PubMed ID: 34971579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What drives transcranial Doppler velocity improvement in paediatric sickle cell anaemia: analysis from the Sickle Cell Clinical Research and Intervention Program (SCCRIP) longitudinal cohort study.
    Estepp JH; Cong Z; Agodoa I; Kang G; Ding J; McCarville MB; Hankins JS; Wang WC
    Br J Haematol; 2021 Jul; 194(2):463-468. PubMed ID: 34131902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial.
    Rankine-Mullings A; Reid M; Soares D; Taylor-Bryan C; Wisdom-Phipps M; Aldred K; Latham T; Schultz WH; Knight-Madden J; Badaloo A; Lane A; Adams RJ; Ware RE
    Br J Haematol; 2021 Nov; 195(4):612-620. PubMed ID: 34291449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRIMARY STROKE PREVENTION IN CHILDREN WITH SICKLE CELL ANEMIA LIVING IN AFRICA: THE FALSE CHOICE BETWEEN PATIENT-ORIENTED RESEARCH AND HUMANITARIAN SERVICE-PART II.
    Debaun MR
    Trans Am Clin Climatol Assoc; 2022; 132():236-248. PubMed ID: 36196180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic.
    DeBaun MR
    Blood; 2020 May; 135(22):1997-1999. PubMed ID: 32282033
    [No Abstract]   [Full Text] [Related]  

  • 10. Hydroxyurea lowers transcranial Doppler flow velocities in children with sickle cell anaemia in a Nigerian cohort.
    Lagunju I; Brown BJ; Sodeinde O
    Pediatr Blood Cancer; 2015 Sep; 62(9):1587-91. PubMed ID: 25847050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stroke and stroke prevention in sickle cell anemia in developed and selected developing countries.
    Bhattacharya P; Sarmah D; Dave KR; Goswami A; Watanabe M; Wang X; Kalia K; Plesnila N; Yavagal DR; Alvarez O
    J Neurol Sci; 2021 Aug; 427():117510. PubMed ID: 34077859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial.
    Ambrose EE; Latham TS; Songoro P; Charles M; Lane AC; Stuber SE; Makubi AN; Ware RE; Smart LR
    Lancet Haematol; 2023 Apr; 10(4):e261-e271. PubMed ID: 36870358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial.
    Wood JC; Cohen AR; Pressel SL; Aygun B; Imran H; Luchtman-Jones L; Thompson AA; Fuh B; Schultz WH; Davis BR; Ware RE;
    Br J Haematol; 2016 Jan; 172(1):122-30. PubMed ID: 26523836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial).
    Galadanci NA; Umar Abdullahi S; Vance LD; Musa Tabari A; Ali S; Belonwu R; Salihu A; Amal Galadanci A; Wudil Jibir B; Bello-Manga H; Neville K; Kirkham FJ; Shyr Y; Phillips S; Covert BV; Kassim AA; Jordan LC; Aliyu MH; DeBaun MR
    Am J Hematol; 2017 Aug; 92(8):780-788. PubMed ID: 28439953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease.
    Kassim AA; DeBaun MR
    Expert Opin Pharmacother; 2014 Feb; 15(3):325-36. PubMed ID: 24392871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia.
    Zimmerman SA; Schultz WH; Burgett S; Mortier NA; Ware RE
    Blood; 2007 Aug; 110(3):1043-7. PubMed ID: 17429008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approximately 40 000 children with sickle cell anemia require screening with TCD and treating with hydroxyurea for stroke prevention in three states in northern Nigeria.
    Galadanci AA; Galadanci NA; Jibir BW; Abdullahi SU; Idris N; Gambo S; Ali Abubakar SA; Kabo NA; Bello-Manga H; Haliru L; Bashir I; Aliyu MH; Galadanci JA; DeBaun MR
    Am J Hematol; 2019 Nov; 94(11):E305-E307. PubMed ID: 31423630
    [No Abstract]   [Full Text] [Related]  

  • 18. Transcranial Doppler screening in Nigerian children with sickle cell disease: A 10-year longitudinal study on the SPPIBA cohort.
    Lagunju IA; Labaeka A; Ibeh JN; Orimadegun AE; Brown BJ; Sodeinde OO
    Pediatr Blood Cancer; 2021 Apr; 68(4):e28906. PubMed ID: 33522690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in management of sickle cell disease.
    Agarwal MB
    Indian J Pediatr; 2003 Aug; 70(8):649-54. PubMed ID: 14510086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of the DREPAGREFFE trial: A prospective controlled multicenter study evaluating the benefit of genoidentical hematopoietic stem cell transplantation over chronic transfusion in sickle cell anemia children detected to be at risk of stroke by transcranial Doppler (NCT 01340404).
    Chevret S; Verlhac S; Ducros-Miralles E; Dalle JH; de Latour RP; de Montalembert M; Benkerrou M; Pondarré C; Thuret I; Guitton C; Lesprit E; Etienne-Julan M; Elana G; Vannier JP; Lutz P; Neven B; Galambrun C; Paillard C; Runel C; Jubert C; Arnaud C; Kamdem A; Brousse V; Missud F; Petras M; Doumdo-Divialle L; Berger C; Fréard F; Taieb O; Drain E; Elmaleh M; Vasile M; Khelif Y; Bernaudin M; Chadebech P; Pirenne F; Socié G; Bernaudin F
    Contemp Clin Trials; 2017 Nov; 62():91-104. PubMed ID: 28821470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.